HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dermatologist Foresees Rise In Topical Probiotic Acne Treatments

This article was originally published in The Rose Sheet

Executive Summary

AAD member Whitney Bowe sees potential for combination therapies incorporating topical probiotic treatments, and a rise in cosmeceutical products featuring probiotics, based on emerging research suggesting benefits in acne and rosacea sufferers.

You may also be interested in...



Probiotic Skin Care Could Be Gutsy Move In US Regulatory Environment

Findings that oral probiotics may not only benefit digestive health but also potentially alleviate inflammatory skin disorders are contentious but have driven uptake of probiotic ingredients by cosmetic players. Market opportunity is growing, but probiotic skin-care claims could be liabilities in the US where FDA increasingly has been citing statements about immunotherapeutic and anti-inflammatory effects in warning letters.

Probiotic Claims Hit Regulatory Wall, But Media Gives An Advertising Lift

Burgeoning research reaches consumers with information that probiotics help with conditions from irritable bowel syndrome to colds, eczema, constipation and diarrhea. “People absorb that information and then they show up and they buy bugs in a bottle,” says health care marketing consultant Kim Wagner.

Probiotics Industry Says FDA Regulatory Bar Is Set Too High

Research on probiotics’ health benefits rapidly grows, but turning studies into label claims lags due to differences between industry, NIH and FDA about standards for claims substantiation. Attendees at a U.S. Pharmacopeia conference outline the challenges to finding common ground

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel